Based in the UK, Britannia Pharmaceuticals Limited specialise in niche products for diseases with small patient populations. In particular they develop products for Parkinson's disease and opiate detoxification (for use by recovering drug addicts). The company develops active compounds into fully licensed pharmaceutical preparations, specialising in clinical trials, formulation work, registration, marketing and sales.

Products

The first product Britannia Pharmaceuticals marketed and developed was Eldepryl (selegiline hydrochloride), a drug designed to increase the levels of dopamine in the brains of Parkinson's sufferers. After identifying the benefit of apomorphine to Parkinson's sufferers, they developed their APO-go range which aims to restore mobility or prevent disability from occurring in Parkinson's disease patients.

Other key products include BritLofex and Crystapen. The first is used for the management of withdrawal symptoms in patients recovering from opiates addiction. Its active ingredient is lofexidine, a non opiate, non-addictive drug. This product can be used in conjunction with Opizone (naltrexone), also a non opiate, non-addictive treatment, which blocks euphoric effects in the 'highs' of opiates like heroin, methadone and codeine.

Crystapen (benzylpenicillin) is a type of penicillin and can be used to treat infections of the ear, throat, chest, heart and bones as well as some sexually transmitted infections, meningitis, blood infections. It can also be administered to mothers in labour to prevent group B streptococcal infection in newborn babies.

britannia-pharma.co.uk

• Return to list